LOS ANGELES, Oct. 3, 2017 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), a
biotechnology company developing immunotherapies for the treatment
of cancer based on Stem-to-T-Cell research, announced today that
Anthony Gringeri, Ph.D., President
and Chief Executive Officer, Steven
Swanson, Ph.D., Sr. VP, Research, and David Fractor, Chief Financial Officer, will
present at the Lytham Partners Virtual Investor Conference on
Wednesday, October 11, 2017 at
2:00 p.m. ET (11:00 a.m. PT). The conference is a virtual event
that is available over the internet. Interested parties may
participate by clicking on either of the links cited below at the
time of the conference.
Event:
|
Lytham Partners
Virtual Investor Conference
|
Date:
|
October 11,
2017
|
Time:
|
2:00 pm ET / 11:00am
PT
|
Webcast:
|
http://investors.imuc.com/events.cfm or
http://www.lythampartners.com/vic.aspx
or by accessing the link
here.
|
Participants during the live event will view the investor
presentation and will be able to pose questions to the speakers in
real-time. A replay of the presentation will be available on demand
following the conclusion of the live event at
http://investors.imuc.com/events.cfm or
http://www.lythampartners.com/vic.aspx or by accessing the link
here.
The presentation will contain forward-looking statements. The
information provided on the presentation is accurate only as of the
time of the virtual presentation, and ImmunoCellular will take no
responsibility for providing updated information except as required
by law.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based
therapies for the treatment of cancer. ImmunoCellular is focused on
advancing its Stem-to-T-Cell research program, which engineers
hematopoietic stem cells to generate cytotoxic T cells. Additional
assets, for which the Company is seeking partners, include
clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are
patient-specific, dendritic cell-based immunotherapies targeting
solid tumors. To learn more about ImmunoCellular, please visit
www.imuc.com.
ImmunoCellular Therapeutics, Ltd.
Contact:
Jane Green
(415) 348-0010 direct
(415) 652-4819 mobile
jane@jmgcomm.com
Investor Relations Contact:
Lytham Partners,
LLC
Joe Dorame, Robert Blum, or
Joseph Diaz
(602) 889-9700
imuc@lythampartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-the-lytham-partners-virtual-investor-conference-on-october-11-2017-at-200pm-et-300529579.html
SOURCE ImmunoCellular Therapeutics, Ltd.